JLK , a medical artificial intelligence (AI) specialist, announced on the 20th that it had received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its AI-based cerebrovascular disease analysis technology.
This patent covers a total of three technologies: ▲Cerebrovascular disease learning device ▲Cerebrovascular disease detection device ▲Cerebrovascular disease learning and detection method, and its core is a multi-stage lesion detection and learning technology that combines CNN (Convolutional Neural Network) and RNN (Recurrent Neural Network) based on 3D TOF MRA (3D sequence magnetic resonance angiography) images.
JLK has implemented an algorithm that sequentially learns and detects spatial, inter-frame, and lesion characteristics of lesions, which is believed to have improved the accuracy of early diagnosis of cerebrovascular diseases such as stroke. In particular, JLK secured exclusive rights to a composite neural network structure that organically combines a CNN-based spatial learning model, an RNN-based frame analysis model, and a lesion detection CNN model, thereby securing a competitive advantage over similar technologies.
This patent approval, along with the seven other US FDA approvals JLK holds, serves as a testament to its global regulatory competitiveness and technological prowess. Building on this momentum, the company plans to accelerate the expansion of its AI solutions in the US healthcare market.
Meanwhile, JLK reported a 120% increase in sales compared to the previous quarter in its second-quarter 2025 semi-annual report. This growth is attributed to increased use of its solutions, particularly in domestic medical institutions, and the expanded use of its AI stroke diagnostic solution.
JLK CEO Kim Dong-min said, “This patent is significant in that it demonstrates that our AI technology has been recognized for its competitiveness in the global market,” and added, “It will serve as an important foundation for expanding cooperation with hospitals and medical institutions in the U.S. in the future, as well as entering the global market.”
- See more related articles
You must be logged in to post a comment.